Stealthy Third Rock start­up poach­es on­col­o­gy ex­ec from No­var­tis — just days af­ter his boss jumped ship

No­var­tis’ on­col­o­gy re­search unit has lost an­oth­er top ex­ec to biotech’s lure.

Pe­ter Ham­mer­man, the glob­al head of on­col­o­gy trans­la­tion­al re­search at NI­BR, re­vealed his jump just days af­ter word got out that his for­mer boss Jeff En­gel­man has launched a can­cer R&D biotech with Loxo founder Josh Bilenker.

His new ti­tle is CSO of MO­MA Ther­a­peu­tics, the stealthy Third Rock start­up that has been beef­ing up its C-suite un­der CEO and Mil­len­ni­um vet Asit Parikh.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER